BG
RVMD icon

Bellevue Group’s Revolution Medicines RVMD Stock Holding History

Bellevue Group’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$196M Sell
1,048,014
-496,442
-32% -$72.5M 4.13% 5
2026
Q1 		$150M Sell
1,544,456
-3,461,263
-69% -$350M 3.57% 6
2025
Q4 		$399M Sell
5,005,719
-568,119
-10% -$37.3M 7.56% 1
2025
Q3 		$260M Buy
5,573,838
+994,538
+22% +$38.9M 5.41% 3
2025
Q2 		$168M Buy
4,579,300
+205,000
+5% +$7.88M 3.71% 10
2025
Q1 		$155M Sell
4,374,300
-12,600
-0.3% -$511K 3.47% 10
2024
Q4 		$192M Sell
4,386,900
-484,460
-10% -$24.4M 3.69% 7
2024
Q3 		$221M Sell
4,871,360
-157,740
-3% -$6.87M 3.58% 6
2024
Q2 		$195M Sell
5,029,100
-44,500
-0.9% -$1.66M 3.17% 8
2024
Q1 		$164M Sell
5,073,600
-17,400
-0.3% -$516K 2.49% 10
2023
Q4 		$146M Buy
5,091,000
+369,500
+8% +$8.88M 2.23% 11
2023
Q3 		$131M Sell
4,721,500
-24,500
-0.5% -$727K 2.11% 12
2023
Q2 		$127M Sell
4,746,000
-1,900
-0% -$46.6K 1.81% 14
2023
Q1 		$103M Sell
4,747,900
-107,262
-2% -$2.64M 1.49% 16
2022
Q4 		$116M Buy
4,855,162
+175,000
+4% +$3.72M 1.53% 17
2022
Q3 		$92.3M Buy
4,680,162
+1,296,900
+38% +$28.5M 1.32% 22
2022
Q2 		$65.9M Buy
3,383,262
+72,600
+2% +$1.41M 0.93% 37
2022
Q1 		$84.5M Sell
3,310,662
-159,500
-5% -$3.47M 0.98% 35
2021
Q4 		$87.3M Buy
3,470,162
+11,357
+0.3% +$320K 0.9% 36
2021
Q3 		$95.2M Buy
3,458,805
+1,604,000
+86% +$46.7M 0.97% 37
2021
Q2 		$58.9M Buy
1,854,805
+789,035
+74% +$27.5M 0.57% 60
2021
Q1 		$48.9M Buy
1,065,770
+1,025,770
+2,564% +$46M 0.52% 60
2020
Q4 		$1.58M Buy
+40,000
New +$1.58M 0.02% 147

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Bellevue Group's RVMD Position: Q2 2026 in Review

Bellevue Group reduced its Revolution Medicines (RVMD) stake by 32% in Q2 2026, selling an estimated $72.5M and leaving 1,048,014 shares worth $196M. The position accounts for 4.13% of the portfolio, ranked #5.

Bellevue Group first reported a position in RVMD in Q4 2020 and has held it in 23 quarters since. The position peaked at $399M in Q4 2025. 690 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Bellevue Group held 1,048,014 shares of Revolution Medicines worth $196M as of Q2 2026.
  • Bellevue Group sold 496,442 Revolution Medicines shares in Q2 2026, an estimated $72.5M.
  • Revolution Medicines made up 4.13% of Bellevue Group's portfolio in Q2 2026, its #5 holding.
  • Bellevue Group first reported a position in Revolution Medicines in Q4 2020 and has held it in 23 quarters since.
  • Bellevue Group's Revolution Medicines position peaked at $399M in Q4 2025.
  • 690 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Bellevue Group's 13F filing for Q2 2026, filed 14 Aug 2026.